Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 43Lymphoid 6Sarcoma 2Other hematologic neoplasm 2Other solid neoplasm 1Myeloid 1CNS 1

Conditions

Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1

Interventions

Azacitidine 62Cyclophosphamide 49fludarabine phosphate 46fludarabine 46Cytarabine 34Decitabine 32venetoclax 27Tacrolimus 21Specimen Handling 21Whole-Body Irradiation 19Mycophenolic Acid 19Melphalan 19Filgrastim 19Busulfan 19Imatinib Mesylate 18ruxolitinib 17Biopsy 15Dasatinib 14Antilymphocyte Serum 14Granulocyte Colony-Stimulating Factor 13Etoposide 13Clofarabine 13Peripheral Blood Stem Cell Transplantation 12Sirolimus 11Methotrexate 11Ipilimumab 11Injections 11Thiotepa 10Stem Cell Transplantation 10thymoglobulin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × pomalidomide × Myeloid × Clear all
NCT02029950 2020-10-14

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 1 Completed
50 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡